<DOC>
	<DOCNO>NCT02617589</DOCNO>
	<brief_summary>The purpose study evaluate patient glioblastoma MGMT-unmethylated ( MGMT gene alter chemical change ) . Patients receive Nivolumab every two week addition radiation therapy , every four week . They compare patient receive standard therapy temozolomide addition radiation therapy .</brief_summary>
	<brief_title>An Investigational Immuno-therapy Study Nivolumab Compared Temozolomide , Each Given With Radiation Therapy , Newly-diagnosed Patients With Glioblastoma ( GBM , Malignant Brain Cancer )</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Males Females , age ≥ 18 year old Newlydiagnosed brain cancer tumor call glioblastoma GBM Tumor test result show MGMT unmethylated type Karnofsky performance status ≥ 70 ( able care self ) Prior treatment GBM ( surgical resection ) Any known tumor outside brain Recurrent secondary GBM Active know suspect autoimmune disease Biopsy le 20 % tumor remove</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>